David T Tse, MD, is a thought-leader in oculoplastic surgery and orbital diseases who pioneered the use of intra-arterial neoadjuvant chemotherapy in treating a lethal lacrimal gland malignancy to improve long-term disease-free survival substantially. He founded the Nasser Al-Rashid Orbital Vision Research Center at Bascom Palmer, the first cure-based orbital research laboratory of its kind in the world, assembling a broad range of research scientists and clinicians focused on finding novel therapies for orbital diseases with significant morbidity and mortality, orbital cancers, traumatic optic nerve injury, and clinical applications for stem cells and biomedical studies. Tse holds five U.S.